Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.90
+0.29 (2.30%)
At close: Jun 18, 2026, 4:00 PM EDT
12.90
0.00 (0.00%)
After-hours: Jun 18, 2026, 7:59 PM EDT
Zevra Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Zevra Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $27.89. The average 1-year stock price forecast is 116.20% higher than the current stock price, while the lowest is $21 (+62.79%) and the highest is $35 (+171.32%).
Price Target: $27.89 (+116.20%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Reiterates $25 → $35 | Buy | Reiterates | $25 → $35 | +171.32% | Jun 10, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +124.81% | Jun 10, 2026 |
| BTIG | BTIG | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +109.30% | Jun 9, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $29 | Buy | Reiterates | $29 | +124.81% | Jun 9, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $26 | Buy | Reiterates | $26 | +101.55% | Jun 9, 2026 |
Financial Forecast
Revenue This Year
145.74M
from 106.47M
Increased by 36.88%
Revenue Next Year
182.24M
from 145.74M
Increased by 25.05%
EPS This Year
1.22
from 1.35
Decreased by -9.38%
EPS Next Year
1.20
from 1.22
Decreased by -2.32%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 164.0M | ||
| Avg | 145.7M | ||
| Low | 135.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 54.0% | ||
| Avg | 36.9% | ||
| Low | 27.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.31 | ||
| Avg | 1.22 | ||
| Low | 1.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.0% | ||
| Avg | -9.4% | ||
| Low | -13.3% |